Gram Research analysis of a 2026 rat study found that vericiguat, a heart failure medication, reduced heart inflammation, cell damage, and scarring in obese, estrogen-deficient female rats. Combining it with estradiol improved more measures than estradiol alone. These results come from animals, so effects in humans remain untested.
Gram Research analysis of a 2026 study found that vericiguat, a medication used for heart failure, reduced several warning signs of heart damage in obese female rats that had lost their ovaries, a model of menopause. The rats were fed a high-fat diet for four months, then treated for four weeks. Vericiguat lowered markers of inflammation, cell damage, and scarring in heart tissue, and it raised the body’s antioxidant defenses. When combined with estradiol, a form of estrogen, the treatment improved more markers than estradiol alone. These results come from animal experiments, so they cannot yet show whether the same benefits would occur in people. Human studies would be needed before any changes to care are considered.
Key Statistics
A 2026 rat study published in the European Journal of Pharmacology found that vericiguat reduced heart inflammation, cell damage, and scarring in obese female rats that had lost their ovaries.
In the same 2026 study, rats were fed a high-fat diet for four months, then received four weeks of treatment with estradiol, vericiguat, or both.
The 2026 study found that combining vericiguat with estradiol improved most heart-related markers more than estradiol alone, though two heart risk indices did not follow this pattern.
The Quick Take
- What they studied: Researchers asked whether vericiguat, a heart failure drug, could reduce heart inflammation, cell damage, and scarring linked to obesity and menopause, alone or together with estradiol, a form of estrogen.
- Who participated: The study used female lab rats. Some had their ovaries removed to mimic menopause, and some were fed a high-fat diet to cause obesity. The exact number of rats was not reported in the study summary.
- Key finding: Vericiguat improved nearly every heart-related marker the researchers measured, including inflammation, cell damage, and scarring. Taking it with estradiol improved more markers than estradiol alone, though not every measure improved this way.
- What it means for you: This is early laboratory evidence in animals, not proof for people. It does not mean anyone should start vericiguat or estrogen for heart protection. Anyone concerned about heart health during menopause or weight gain should talk with a doctor.
The Research Details
The researchers used female rats divided into two main groups. One group had their ovaries surgically removed, which causes a sudden drop in estrogen similar to menopause. The other group had a sham surgery, which included the same steps without removing the ovaries. Both groups were then given either a standard diet or a high-fat diet for four months, so some animals became obese.
After the four-month diet period, the rats received four weeks of treatment. Some received estradiol, some received one of two doses of vericiguat, and some received both. The researchers then examined heart tissue and blood samples. They measured body weight, markers of cell damage and antioxidant capacity, blood fat ratios linked to heart disease risk, a protein that signals inflammation, a protein that drives scarring, and a protein involved in heart cell signaling.
This design lets researchers compare animals that differ in only one factor at a time, such as ovary removal, diet, or treatment. That makes it easier to see what caused a change. Because the study used a controlled laboratory setting, the results are cleaner than observational data, but they are still limited to animals.
Comparing groups side by side helps show whether a drug actually causes changes or whether the changes happened by chance. Measuring many markers in the same animals also shows whether a treatment affects the body in a connected way, rather than just one isolated measure.
Using a model of ovary removal plus a high-fat diet is useful because it mirrors some of the heart changes seen in women after menopause who also carry extra weight. This gives researchers a practical way to test ideas before moving to human trials, which are slower, more expensive, and carry more safety requirements.
The study was published in a peer-reviewed pharmacology journal, which means other scientists reviewed the work before publication. The design included control groups and multiple comparison groups, which strengthens confidence in the results. The study summary does not report the exact number of rats per group, which makes it harder to judge how much weight to give each result.
Because this is an animal study, the findings may not translate directly to humans. Rats differ from people in metabolism, lifespan, and how drugs are processed. Readers should treat the results as an early signal that needs confirmation in people.
What the Results Show
Rats that lost their ovaries and ate a high-fat diet showed clear signs of trouble. They gained more weight, had higher blood fat ratios linked to heart disease, showed more cell damage, and had lower antioxidant defenses. Their heart tissue also showed more inflammation and more scarring.
Both estradiol and vericiguat reversed many of these changes. Treated animals had lower blood fat ratios, less cell damage, less inflammation, and less scarring in heart tissue. Their antioxidant defenses were stronger than those of untreated animals. Put simply, both treatments moved the heart tissue in a healthier direction.
When the two treatments were combined, the results were generally better than estradiol alone for most measures. The researchers reported that the combination improved all measured markers except two heart risk indices. Statistical tests also showed that the two treatments interacted in certain measures, meaning the effect of one depended partly on the other. These measures included an antioxidant balance ratio, scarring content, and a growth-related protein that drives scarring.
The researchers also tracked a protein called PKG-I, which is involved in helping heart cells relax and respond to signals. Vericiguat and estradiol both raised levels of this protein, which had dropped in the obese, estrogen-deficient animals. This suggests the treatments may support healthier heart cell signaling, though the study does not show how much this matters for heart function.
The two heart risk indices did not improve as clearly as the other measures when vericiguat was added to estradiol. This is an important detail because it shows that the combination did not help every measure. Researchers need to look more closely at why these indices responded differently.
Vericiguat is approved for certain patients with heart failure, and it works by boosting a signaling pathway that relaxes blood vessels and supports heart function. Earlier research has linked this pathway to reduced inflammation and scarring in heart tissue, which fits with the findings here. Estrogen is also known to protect blood vessels and heart tissue, and loss of estrogen during menopause is linked to higher heart disease risk.
This study adds to that picture by suggesting that vericiguat may work alongside estrogen rather than only on its own. Still, most of the evidence for vericiguat comes from people with diagnosed heart failure, not from healthy women going through menopause. This study is an early step, not a replacement for those findings.
The study was done in rats, so results may not apply to humans. Rats process drugs differently, and their heart disease patterns are not identical to human patterns. The study summary did not report the number of animals per group, which makes it harder to judge the strength of the results. The study also lasted only four weeks of treatment, so it does not show whether benefits last over years.
The researchers measured markers in tissue and blood rather than measuring heart outcomes such as heart attacks or heart function over time. Changes in these markers do not automatically mean the heart is healthier in a way that prevents disease. Finally, the study tested only one type of estrogen and two doses of vericiguat, so other forms and doses remain unknown.
The Bottom Line
Based on this single animal study, the evidence is preliminary. Researchers should consider testing vericiguat in human studies, especially in women going through menopause who also have obesity, before drawing conclusions. Confidence in these results is low to moderate for the animal model and low for any human application at this time.
People should not start vericiguat or estrogen to protect their hearts based on this study. Hormone therapy and prescription heart drugs carry risks and must be decided with a doctor who knows a person’s full medical history.
Researchers who study heart disease, menopause, and obesity should pay attention because this study points to a possible new direction for testing. Doctors who treat women with heart failure or heart disease risk may find it useful as background information.
Most general readers do not need to change anything based on this study. Women going through menopause, or those with obesity and heart disease risk, should talk with their doctors about proven steps such as diet, exercise, blood pressure, and cholesterol management.
Animal studies like this one usually take many years to lead to human treatments. Testing in people typically moves through several phases, each lasting one to several years, before a drug could be approved for a new use. Even if future human research is positive, it could be a decade or more before any new recommendation reaches everyday care.
Frequently Asked Questions
Can vericiguat protect the heart during menopause?
A 2026 animal study found that vericiguat reduced heart inflammation and scarring in obese female rats without ovaries. Results in humans have not been tested, so it is not yet known whether it would protect women’s hearts during menopause.
What is vericiguat used for?
Vericiguat is a prescription medication approved for certain adults with heart failure. It works by boosting a signaling pathway that relaxes blood vessels and supports heart function. Doctors decide whether it is appropriate for each patient.
Does estrogen help protect the heart in obese women after menopause?
Estrogen loss during menopause is linked to higher heart disease risk, and estradiol improved several heart markers in a 2026 rat study. Human evidence is more complex, so women should discuss hormone therapy risks and benefits with their doctor.
Is it safe to take heart medication to prevent heart disease without a diagnosis?
Preventive use of prescription heart medication without a diagnosis is not supported by current evidence from this study alone. Animal findings do not establish safety or benefit in healthy people, so anyone considering it should consult a qualified healthcare provider first.
Want to Apply This Research?
- Track weekly body weight, waist circumference, and blood pressure readings at the same time of day. If you have access to lab results, record your fasting cholesterol and triglyceride numbers every three to six months so trends are easy to see.
- Use the app to set a realistic goal of 150 minutes of moderate activity per week, such as brisk walking, and log each session. Pair this with a daily step target and a simple food log that tracks fiber, vegetables, and added sugar to support heart health while you talk with your doctor about proven options.
- Review your logged trends monthly and share summaries with your healthcare provider at each visit. Over the long term, watch for steady changes in weight, blood pressure, and blood fat numbers, and flag any sudden symptoms such as chest discomfort or shortness of breath for prompt medical attention.
This article summarizes an animal study in rats and is for general educational purposes only. The findings have not been tested in humans and should not be used to start, stop, or change any medication, including vericiguat or estrogen therapy. Talk with a qualified healthcare provider before making decisions about heart health, menopause treatment, or weight management.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.